Published in Nature on April 27, 2006
Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest (2007) 5.38
Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet (2008) 4.31
Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ (2011) 3.65
The immune system and cardiac repair. Pharmacol Res (2008) 3.42
Regulation of the inflammatory response in cardiac repair. Circ Res (2012) 3.21
Inflammation, insulin resistance, and diabetes--Mendelian randomization using CRP haplotypes points upstream. PLoS Med (2008) 1.95
Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med (2010) 1.89
Blockade of self-reactive IgM significantly reduces injury in a murine model of acute myocardial infarction. Cardiovasc Res (2010) 1.78
Effects of human C-reactive protein on pathogenesis of features of the metabolic syndrome. Hypertension (2011) 1.71
A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation. PLoS Med (2010) 1.60
Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial). J Cardiovasc Electrophysiol (2010) 1.57
The evolving role of C-reactive protein in atherothrombosis. Clin Chem (2008) 1.48
Acute modulation of toll-like receptors by insulin. Diabetes Care (2008) 1.46
B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med (2013) 1.43
Neurokinin 3 receptor and phosphocholine transferase: missing factors for pathogenesis of C-reactive protein in preeclampsia. Hypertension (2014) 1.41
The HDL proteome: a marker--and perhaps mediator--of coronary artery disease. J Lipid Res (2008) 1.35
Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res (2008) 1.33
The connection between C-reactive protein and atherosclerosis. Ann Med (2008) 1.29
The association of C-reactive protein and CRP genotype with coronary heart disease: findings from five studies with 4,610 cases amongst 18,637 participants. PLoS One (2008) 1.28
Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis (2009) 1.26
C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol (2007) 1.25
Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) (2009) 1.24
Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle (2012) 1.21
C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis (2008) 1.21
C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells. J Immunol (2008) 1.21
C-reactive protein collaborates with plasma lectins to boost immune response against bacteria. EMBO J (2007) 1.19
Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk. JAMA Psychiatry (2014) 1.18
Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men. J Thromb Haemost (2009) 1.16
Complement factor H binds to denatured rather than to native pentameric C-reactive protein. J Biol Chem (2008) 1.15
CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Transl Med (2009) 1.15
C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler Thromb Vasc Biol (2011) 1.15
Scientific and clinical challenges in sepsis. Curr Pharm Des (2009) 1.14
Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation. Eur J Epidemiol (2008) 1.14
Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from four U.K. prospective cohort studies. Diabetes Care (2011) 1.11
Local inflammation induces complement crosstalk which amplifies the antimicrobial response. PLoS Pathog (2009) 1.10
Does high C-reactive protein concentration increase atherosclerosis? The Whitehall II Study. PLoS One (2008) 1.09
Phosphoethanolamine-complexed C-reactive protein: a pharmacological-like macromolecule that binds to native low-density lipoprotein in human serum. Clin Chim Acta (2008) 1.06
C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death. J Neurol (2009) 1.05
Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart (2007) 1.04
Evaluating the causal relevance of diverse risk markers: horizontal systematic review. BMJ (2009) 1.02
Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proc Natl Acad Sci U S A (2010) 1.02
Evaluation of Mangosteen juice blend on biomarkers of inflammation in obese subjects: a pilot, dose finding study. Nutr J (2009) 0.99
A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans. Mol Ther Nucleic Acids (2012) 0.97
Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol (2015) 0.96
Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia. Arterioscler Thromb Vasc Biol (2010) 0.96
C-reactive protein and nitric oxide levels in ischemic stroke and its subtypes: correlation with clinical outcome. Inflammation (2012) 0.94
C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes. Clin Chem (2008) 0.94
Marked differences in CRP genotype frequencies between the Fulani and sympatric ethnic groups in Africa. Malar J (2009) 0.94
Inhibition of endothelial nitric oxide synthase by C-reactive protein: clinical relevance. Clin Chem (2008) 0.92
Association of TNF-α with insulin resistance in type 2 diabetes mellitus. Indian J Med Res (2012) 0.91
Dietary saturated fat/cholesterol, but not unsaturated fat or starch, induces C-reactive protein associated early atherosclerosis and ectopic fat deposition in diabetic pigs. Cardiovasc Diabetol (2011) 0.91
Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents. Clin Chem (2008) 0.90
C-reactive protein and prognosis in diabetes: getting to the heart of the matter. Diabetes (2009) 0.89
Linking inflammation and thrombosis: Role of C-reactive protein. World J Cardiol (2010) 0.89
C-reactive protein and vein graft disease: evidence for a direct effect on smooth muscle cell phenotype via modulation of PDGF receptor-beta. Am J Physiol Heart Circ Physiol (2008) 0.88
Should C-reactive protein be a target of therapy? Diabetes Care (2011) 0.88
Vein graft failure. J Vasc Surg (2013) 0.88
C-reactive protein induces M-CSF release and macrophage proliferation. J Leukoc Biol (2008) 0.88
C-reactive protein promotes atherosclerosis by increasing LDL transcytosis across endothelial cells. Br J Pharmacol (2014) 0.88
Oestrogen-mediated cardioprotection following ischaemia and reperfusion is mimicked by an oestrogen receptor (ER)alpha agonist and unaffected by an ER beta antagonist. J Endocrinol (2008) 0.88
Autonomic neuropathy in diabetes mellitus. Front Endocrinol (Lausanne) (2014) 0.87
Nasal vaccination with troponin reduces troponin specific T-cell responses and improves heart function in myocardial ischemia-reperfusion injury. Int Immunol (2009) 0.86
Affinity of C-reactive protein toward FcgammaRI is strongly enhanced by the gamma-chain. Am J Pathol (2007) 0.86
Socioeconomic indices as independent correlates of C-reactive protein in the National Longitudinal Study of Adolescent Health. Psychosom Med (2013) 0.86
C-reactive protein in human atherogenesis: facts and fiction. Mediators Inflamm (2014) 0.86
Recognition functions of pentameric C-reactive protein in cardiovascular disease. Mediators Inflamm (2014) 0.86
Combination stem cell therapy for heart failure. Int Arch Med (2010) 0.85
Prognostic value of admission C-reactive protein in stroke patients undergoing iv thrombolysis. J Neurol (2008) 0.85
Suppression of coronary atherosclerosis by helix B surface Peptide, a nonerythropoietic, tissue-protective compound derived from erythropoietin. Mol Med (2013) 0.83
C-reactive protein and coronary heart disease: all said--is not it? Mediators Inflamm (2014) 0.83
Effects of heme oxygenase-1 upregulation on blood pressure and cardiac function in an animal model of hypertensive myocardial infarction. Int J Mol Sci (2013) 0.83
C-reactive protein and subclinical cardiovascular disease among African-Americans: (the Jackson Heart Study). J Cardiovasc Med (Hagerstown) (2014) 0.83
Novel cardiac-specific biomarkers and the cardiovascular continuum. Biomark Insights (2012) 0.83
Cardiac troponin I levels in canine pyometra. Acta Vet Scand (2007) 0.83
Plasma C-Reactive Protein and Clinical Outcomes after Acute Ischemic Stroke: A Prospective Observational Study. PLoS One (2016) 0.82
C-reactive protein (CRP) is essential for efficient systemic transduction of recombinant adeno-associated virus vector 1 (rAAV-1) and rAAV-6 in mice. J Virol (2013) 0.82
Heme interacts with c1q and inhibits the classical complement pathway. J Biol Chem (2011) 0.82
Determination of inflammatory biomarkers in patients with COPD: a comparison of different assays. BMC Med Res Methodol (2012) 0.81
Jupiter to Earth: CRP promotes atherothrombosis. Metab Syndr Relat Disord (2009) 0.81
Novel markers of peripheral arterial disease. Vasc Med (2009) 0.81
Human C-reactive protein accentuates macrophage activity in biobreeding diabetic rats. J Diabetes Complications (2012) 0.81
Relationship between deep venous thrombosis and inflammatory cytokines in postoperative patients with malignant abdominal tumors. Braz J Med Biol Res (2014) 0.81
Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. J Immunol Methods (2012) 0.81
Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes. Mediators Inflamm (2015) 0.80
Arsenite activates NFκB through induction of C-reactive protein. Toxicol Appl Pharmacol (2012) 0.80
Value of C-reactive protein in predicting left ventricular remodelling in patients with a first ST-segment elevation myocardial infarction. Mediators Inflamm (2012) 0.80
The role and clinical significance of high-sensitivity C-reactive protein in cardiovascular disease. Korean Circ J (2012) 0.80
C-reactive protein--does it promote vascular disease? Nephrol Dial Transplant (2006) 0.80
Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction. Inflamm Res (2012) 0.80
Value of C-reactive protein as a risk factor for acute coronary syndrome: a comparison with apolipoprotein concentrations and lipid profile. Mediators Inflamm (2012) 0.80
The Dual Complexity of PTX3 in Health and Disease: A Balancing Act? Trends Mol Med (2016) 0.79
Impaired arterial stiffness in systemic lupus ertythematosus - correlations with inflammation markers. Curr Health Sci J (2012) 0.79
The Impact of Ischemic Time on the Predictive Value of High-Sensitivity C-Reactive Protein in ST-Segment Elevation Myocardial Infarction Patients Treated by Primary Percutaneous Coronary Intervention. Korean Circ J (2013) 0.79
Increased preoperative C-reactive protein levels are associated with inhospital death after coronary artery bypass surgery. Inflammation (2012) 0.79
Salivary constituents and acidogenic microbial counts in coronary artery bypass graft patients from baseline to three-years after operation. Clin Oral Investig (2007) 0.79
Targeting BNIP3 in inflammation-mediated heart failure: a novel concept in heart failure therapy. Heart Fail Rev (2016) 0.79
Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP? Curr Atheroscler Rep (2011) 0.78
Targeting C-reactive protein levels using high-dose atorvastatin before coronary artery bypass graft surgery. Exp Clin Cardiol (2008) 0.78
Inhibiting C-reactive protein for the treatment of cardiovascular disease: promising evidence from rodent models. Mediators Inflamm (2014) 0.78
Early inflammatory markers are independent predictors of cardiac allograft vasculopathy in heart-transplant recipients. PLoS One (2014) 0.78
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med (2004) 15.30
NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity (2004) 13.55
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
C-reactive protein: a critical update. J Clin Invest (2003) 11.77
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Mechanism of auxin perception by the TIR1 ubiquitin ligase. Nature (2007) 8.21
Molecular mechanisms of amyloidosis. N Engl J Med (2003) 7.75
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 5.61
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis (2005) 5.20
Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 5.19
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Natural history and outcome in systemic AA amyloidosis. N Engl J Med (2007) 4.54
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med (2002) 4.47
Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS (2007) 4.40
T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging (2013) 4.21
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care (2008) 4.10
The protofilament structure of insulin amyloid fibrils. Proc Natl Acad Sci U S A (2002) 4.08
Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med (2013) 3.97
Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med (2003) 3.86
A tandem mass spectrometer for improved transmission and analysis of large macromolecular assemblies. Anal Chem (2002) 3.83
Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat Chem (2009) 3.66
Determining the stoichiometry and interactions of macromolecular assemblies from mass spectrometry. Nat Protoc (2007) 3.64
Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging (2013) 3.53
Ion mobility-mass spectrometry analysis of large protein complexes. Nat Protoc (2008) 3.51
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS (2010) 3.47
In vitro reconstitution of the human RISC-loading complex. Proc Natl Acad Sci U S A (2008) 3.43
Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr (2007) 3.40
Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med (2007) 3.38
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Evidence for macromolecular protein rings in the absence of bulk water. Science (2005) 3.26
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol (2007) 3.12
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70
Structures of SAS-6 suggest its organization in centrioles. Science (2011) 2.67
Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation (2008) 2.64
Structure of an Hsp90-Cdc37-Cdk4 complex. Mol Cell (2006) 2.62
Collision cross sections of proteins and their complexes: a calibration framework and database for gas-phase structural biology. Anal Chem (2010) 2.62
Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum (2002) 2.58
Protein complexes in the gas phase: technology for structural genomics and proteomics. Chem Rev (2007) 2.57
Structural organization of the 19S proteasome lid: insights from MS of intact complexes. PLoS Biol (2006) 2.56
Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS (2005) 2.51
Mass spectrometry reveals modularity and a complete subunit interaction map of the eukaryotic translation factor eIF3. Proc Natl Acad Sci U S A (2008) 2.50
The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS (2006) 2.42
Micelles protect membrane complexes from solution to vacuum. Science (2008) 2.40
Molecular recycling within amyloid fibrils. Nature (2005) 2.39
The role of mass spectrometry in structure elucidation of dynamic protein complexes. Annu Rev Biochem (2007) 2.39
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood (2013) 2.38
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS (2006) 2.35
In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med (2009) 2.34
Mass measurements of increased accuracy resolve heterogeneous populations of intact ribosomes. J Am Chem Soc (2006) 2.31
Symmetrical modularity of the COP9 signalosome complex suggests its multifunctionality. Structure (2009) 2.30
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS (2008) 2.27
Assembly reflects evolution of protein complexes. Nature (2008) 2.27
Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res (2013) 2.26
Updates in cardiac amyloidosis: a review. J Am Heart Assoc (2012) 2.21
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol (2010) 2.20
Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum (2002) 2.19
Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. Clin Chem (2003) 2.15
Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. EMBO J (2003) 2.11
The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nat Struct Mol Biol (2010) 2.08
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Structural insights into the activity of enhancer-binding proteins. Science (2005) 2.04
Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson (2008) 2.01
Newly diagnosed HIV infections: review in UK and Ireland. BMJ (2005) 2.00
The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med (2005) 1.97
3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet (2006) 1.97
Tandem mass spectrometry reveals the quaternary organization of macromolecular assemblies. Chem Biol (2006) 1.96
Crystal structures of truncated alphaA and alphaB crystallins reveal structural mechanisms of polydispersity important for eye lens function. Protein Sci (2010) 1.95
Structural basis for protein-protein interactions in the 14-3-3 protein family. Proc Natl Acad Sci U S A (2006) 1.95
Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res (2005) 1.91
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS (2009) 1.90
Fish is food--the FAO's fish price index. PLoS One (2012) 1.86
An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4. J Biol Chem (2009) 1.85
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med (2015) 1.84
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther (2008) 1.83
No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002). AIDS (2005) 1.82
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81